A shocking revelation has come to light: despite clear safety warnings, a significant number of older Americans with dementia are being prescribed risky brain-altering drugs. This practice, which has been discouraged by clinical guidelines for years, continues to put vulnerable individuals at risk.
According to a study published in JAMA, one in four Medicare beneficiaries with dementia receives these medications, linked to serious side effects such as falls, confusion, and hospitalization. While the overall prescription rate has slightly decreased over nine years, from 20% to 16%, the concern remains for those with cognitive impairment.
Dr. John N. Mafi, a senior author of the study, highlights the issue: "Over two-thirds of patients receiving these prescriptions lacked a documented clinical indication in 2021. This suggests a high level of potentially harmful and inappropriate prescribing."
The study focused on five drug classes commonly prescribed to older adults: antidepressants with strong anticholinergic properties, antipsychotics, barbiturates, benzodiazepines, and non-benzodiazepine hypnotics. The findings revealed that nearly 22% of older adults with cognitive impairment but without dementia were prescribed these medications, and this number rose to approximately 25% for those with dementia.
Here's where it gets controversial: prescription trends varied significantly by medication class. Benzodiazepines and sleep medications saw a decline, but antipsychotic prescriptions increased. Additionally, prescriptions for anticholinergic antidepressants and barbiturates remained relatively stable.
And this is the part most people miss: the study also found that clinically justified prescriptions decreased, while potentially inappropriate prescriptions saw a notable decline. This improvement is largely attributed to reduced prescriptions for benzodiazepines and sleep medications.
However, the findings are not without limitations. The study lacked Medicare Advantage data, potentially missing important clinical information, and focused primarily on prescribing prevalence rather than cumulative exposure.
Dr. Annie Yang, who led the study, emphasizes the importance of collaboration between patients, caregivers, and physicians: "CNS-active prescriptions may be appropriate in some cases, but it is crucial for older patients and their caregivers to work closely with their doctors to ensure the medications are necessary. When inappropriate, alternative treatments should be considered, and the possibility of tapering or stopping the medication should be explored."
This study, funded by the National Institutes of Health/National Institute on Aging, highlights the need for improved quality and safety of care for older Americans. It raises important questions about the appropriate use of these medications and the potential risks they pose to vulnerable populations. What are your thoughts on this issue? Feel free to share your opinions and experiences in the comments below!
